Bio pet food startup Limpid announced that it has signed a memorandum of understanding (MOU) with pet healthcare startup Doctor Tail to enter the U.S. pet healthcare market.
Under this agreement, Limpid will launch a full-scale US market entry strategy for its "AI Pet Precision Nutrition Solution," currently under development. The collaboration will leverage Dr. Tail's accumulated data and network in the US.
DoctorTail has secured relevant data through over 270,000 AI veterinary consultations with over 700,000 pet owners in the United States. The company uses cloud-based technology to collect and manage pet medical records and health care pattern data.
This data will be used to refine Limpid's AI-powered pet precision nutrition solution for the US market. Based on this data, Limpid plans to develop customized nutrition solutions tailored to the needs of American pet owners.
The two companies also agreed to collaborate on analyzing trends and consumer behavior in the US pet healthcare market, as well as identifying local partners. They also plan to explore mid- to long-term collaboration plans that take into account the unique technologies and service offerings of both companies.
Limpid CEO Kim Hee-soo emphasized the importance of developing a strategy based on local data for entering the US market. DoctorTail CEO Lee Dae-hwa explained that the company's US pet health management data could be utilized by domestic pet tech companies for their overseas expansion.
- See more related articles
You must be logged in to post a comment.